Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Hood

Internal Medicine Lexington, KY Medical Doctor

NPI 1255330387 CMS profile 11826

2101 Nicholasville Rd, Suite 106, Lexington, KY 40503

Open in the dashboard

General payments

$8,954

536 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Hood of Lexington, KY is reported in the CMS Open Payments database as having received $8,954 across 536 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,380 77
2024 General $1,248 68
2023 General $1,659 81
2022 General $1,349 80
2021 General $1,009 60
2020 General $1,066 75
2019 General $1,244 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Hood
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gregory Hood were reported at $1,380. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gregory Hood Internal Medicine median Middle half National median
2019 $1,244 $159 $48–$570 $163
2020 $1,066 $119 $33–$402 $114
2021 $1,009 $135 $37–$521 $132
2022 $1,349 $141 $42–$496 $149
2023 $1,659 $149 $45–$519 $160
2024 $1,248 $154 $47–$537 $164
2025 $1,380 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $914 59 payments
  2. Pfizer Inc. $779 44 payments
  3. Lilly USA, LLC $598 38 payments
  4. Amgen Inc. $540 33 payments
  5. Novartis Pharmaceuticals Corporation $532 31 payments
  6. GlaxoSmithKline, LLC. $444 29 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $354 21 payments
  8. AbbVie, Inc. $350 26 payments
  9. Janssen Pharmaceuticals, Inc $274 19 payments
  10. Sanofi-Aventis U.S. LLC $267 20 payments
  11. Other $3,903 216 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,912 532 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26 2 payments
  3. Education $16 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $621 39 payments
  2. RYBELSUS $413 20 payments
  3. LEQVIO $327 18 payments
  4. MOUNJARO $318 18 payments
  5. GEMTESA $285 14 payments
  6. Repatha $271 18 payments
  7. PAXLOVID $262 10 payments
  8. XARELTO $239 16 payments
  9. LOREEV XR $234 11 payments
  10. EVENITY $230 13 payments
  11. Other $8,460 536 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 175 drugs

Part D claims

10,544

Median for Internal Medicine: 777

Drug cost

$1,577,134

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 190 $216,539
Ozempic Semaglutide Brand 166 $198,023
Entresto Sacubitril/Valsartan Brand 86 $106,739
Jardiance Empagliflozin Brand 74 $104,379
Repatha Sureclick Evolocumab Brand 65 $83,199
Gemtesa Vibegron Brand 80 $78,997
Mounjaro Tirzepatide Brand 65 $67,080
Trulicity Dulaglutide Brand 45 $59,742
Xarelto Rivaroxaban Brand 45 $54,125
Nuplazid Pimavanserin Tartrate Brand 31 $49,538

The 10 drugs with the highest cost, of 175 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$101,163

Of which drugs: $10,066

Medicare patients

229

Average age 77

Services billed

1,861

128 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 34%
Diabetes 32%
Chronic kidney disease 30%
Atrial fibrillation 22%
Depression 22%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 111 111 $9,000

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $120
$120 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $116
$116 — —
Ozempic
  • Novo Nordisk Inc $87
$87 166 —
MOUNJARO
  • Lilly USA, LLC $72
$72 65 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

536 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record